| Autor: |
Medina-González, Ramón, Zaragoza, Jose J., Hernández-Barajas, Eduardo M., Correa-de Leon, Juarez, Claure-Del Granado, Rolando, Vazquez-Rangel, Armando, Pineda-Segura, Liliana M., Franco-Garcia, Martha K., Chávez-Alonso, Gael, Gómez-Fregoso, Juan A., Rodríguez-García, Francisco G., Navarro-Blackaller, Guillermo, Alcantar-Vallin, Luz, Martínez Gallardo-González, Alejandro, Abundis-Mora, Gabriela J., García-García, Guillermo, Chávez-Iñiguez, Jonathan S. |
| Předmět: |
|
| Zdroj: |
Renal Failure; 2024, Vol. 46 Issue 1, p1-11, 11p |
| Abstrakt: |
Introduction: A reduction in platelet count in critically ill patients is a marker of severity of the clinical condition. However, whether this association holds true in acute kidney injury (AKI) is unknown. We analyzed the association between platelet reduction in patients with AKI and major adverse kidney events (MAKE). Methods: In this retrospective cohort, we included AKI patients at the Hospital Civil of Guadalajara, in Jalisco, Mexico. Patients were divided according to whether their platelet count fell >21% during the first 10days. Our objectives were to analyze the associations between a platelet reduction >21% and MAKE at 10days (MAKE10) or at 30-90days (MAKE30-90) and death. Results: From 2017 to 2023, 400 AKI patients were included, 134 of whom had a>21% reduction in platelet count. The mean age was 54years, 60% were male, and 44% had sepsis. The mean baseline platelet count was 194 x 103 cells/µL, and 65% of the KDIGO3 patients met these criteria. Those who underwent hemodialysis (HD) had lower platelet counts. After multiple adjustments, a platelet reduction >21% was associated with MAKE10 (OR 4.2, CI 2.1-8.5) but not with MAKE30-90. The mortality risk increased 3-fold (OR 2.9, CI 1.1-7.7, p=0.02) with a greater decrease in the platelets (<90 x 103 cells/µL). As the platelets decreased, the incidence of MAKE was more likely to increase. These associations lost significance when accounting for starting HD. Conclusion: In our retrospective cohort of patients with AKI, a>21% reduction in platelet count was associated with MAKE. Our results are useful for generating hypotheses and motivating us to continue studying this association with a more robust design. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
